Integrated Biologics Manufacturing In Europe: What It Looks Like In Practice

By Barnara Fedejko-Kap, Associate VP Development

Unifying biopharmaceutical development and commercial production within a single regional framework helps organizations streamline complex supply chains and minimize technology transfer risks. Implementing an end-to-end operational model—from early cell line engineering and analytical testing to scalable single-use good manufacturing practice facilities—ensures rigorous compliance with international standards set by global regulatory bodies. By leveraging mirrored infrastructure and smart scheduling workflows, biopharmaceutical developers can accelerate clinical progression, reduce operational variability, and optimize manufacturing throughput.

Explore the full asset to learn how integrated European facilities can support your next biological program from initial discovery to full-scale commercialization.